BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 12, 2019--
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that its President and Chief Executive Officer, Jayson Dallas,
M.D., will present at the JMP Securities Life Sciences Conference onWednesday, June 19, 2019 at 2:30 p.m. E.T. in New York City.
A live webcast of the presentation will be accessible on the Events page
under the Investor Relations section of the Aimmune website at www.aimmune.com.
A replay will also be available following the webcast.
Aimmune Therapeutics, Inc., is a biopharmaceutical company developing
oral treatments for life-threatening food allergies. The company’s Characterized
(CODIT™) approach is intended to provide meaningful levels of protection
against allergic reactions resulting from exposure to food allergens by
desensitizing patients with defined, precise amounts of key allergens.
Aimmune’s first, investigational, complex biologic product, AR101, is
being developed as a treatment to reduce the frequency and severity and
adverse events following exposure to peanut. The BLA for AR101 is under
review by the FDA, which granted AR101 Breakthrough Therapy Designation
in 2015 for the desensitization of peanut-allergic patients 4 to 17
years of age. The Allergenic Products Advisory Committee (APAC) of the
FDA will review the BLA for AR101 at a meeting scheduled for September
13, 2019. Aimmune has filed an IND application for its second product,
AR201 for the treatment of egg allergy, and intends to start a
randomized phase 2 clinical trial in mid-2019. For more information,
please see www.aimmune.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005156/en/
Source: Aimmune Therapeutics, Inc.
(650) 376-5582 or
(312) 858 3469 or